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Abstract
Background: Serous adenomas represent 1-2% of pancreatic neoplasms and typically are asymptomatic not
requiring any treatment and simple observation is the option of choice. Although, they carry a realistic risk of
malignancy despite the general view that they never become malignant. We report a case, which, according to
our best knowledge is the 27th case reported in the literature.
Methods: We reviewed the literature by performing a search in Pub Med and Medline.
Results: A 86-year old patient known to have a serous cystadenoma of the pancreas treated conservatively
through a close clinical and radiological follow up which was unattended for 4 years ending up to our emergency
department suffering an acute abdomen. Exploratory laparotomy revealed a perforated prepyloric ulcer which was
treated accordingly. Patient died some weeks later due to severe medical co morbidities.
Conclusion: Serous cystic neoplasms of the pancreas carry a realistic risk of malignancy despite the general view
that they never become malignant. In our opinion the treatment strategy of serous cystic neoplasms of the
pancreas should be aggressive even in cases of remote metastases since prognosis of the disease is satisfactory
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Background
Malignant cystic tumors of the pancreas are very rare,
accounting for about 1% of all pancreatic malignancies
[1,2]. Pancreatic cystic neoplasms comprise 1-2% of pan-
creatic lesions [3] and most of these lesions are cystadeno-
mas[3,4]. In 1978, Compagno and Oertel [5] issued an
histopathologic classification of cystic neoplasms of the
pancreas identifying two different types with different bio-
logical behavior. The first type is considered the serous
cystic neoplasm and the serous cystadenoma represents
numerically the most common entity. Also called glyco-
gen-rich cystadenoma or microcystic adenoma is generally
considered to be a benign condition although serous cysta-
denocarcinoma is a rare but known malignant condition
described in the literature. Mucinous cystic neoplasms of
the pancreas are the other type of lesions and possess the
more frequent ability to transform to its malignant coun-
terpart, namely mucinous cystadenocarcinoma [6]. Today
serous and mucinous pancreatic neoplasms are classified
according to the WHO nomenclature as tumors of the
exocrine pancreas [7].
According to the latest WHO classification these
tumors are called serous cystic neoplasms, which are
cystic epithelial neoplasms composed of glycogen-rich,
epithelial cells that produce a watery fluid similar to
serum. Most of these are benign (serous cystadenomas),
and in rare cases are malignant (serous cystadenocarci-
noma). Serous adenoma has four variants: macrocystic
serous cystic neoplasm, solid serous neoplasm, von
Hippel-Lindau (VHL)-associated serous cystic neoplasm,
and mixed serous-neuroendocrine neoplasm. The term
serous cystadenoma refers to microcystic type (the most
frequent) of the neoplasm [4].
In 1989, George et al [8] first reported a case of serous
microcystic adenoma behaving in a malignant fashion
and since then, according to our best knowledge, 26
cases have been reported in the literature. According to
WHO the prevalence of malignancy of serous cystic
neoplasms of the pancreas is 1%- 3% [4]. We report a
case of serous cystadenocarcinoma with extensive local
invasion and liver metastases.
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Case presentation
An 86-year old woman presented at the emergency
department suffering from severe acute upper abdominal
pain. Her past medical history included hypertension,
diabetes mellitus, coronary heart disease, atrial fibrilla-
tion, chronic obstructive pulmonary disease and twenty
years before she had an omphalocele repair. The patient
was in a close clinical and radiological follow up for mon-
itoring a pancreatic serous cystadenoma diagnosed inci-
dentally with a computed tomography (CT) scan 10 years
earlier. The lesion was extensively studied with magnetic
resonance imaging (MRI), endoscopic ultrasound (EUS),
fine needle aspiration (FNA), serology and blood test
screening. At that time she was addressed for a routine
year follow up scan which she attended regularly for six
years. Patient did not attend her follow up time table for
the last four years. Upon admission to the emergency
department, chest and abdominal x-rays were performed
and turned out inconclusive. Routine laboratory studies
revealed marked leukocytosis, severe anemia, and blood
glucose levels exceeding 500 mg/dl. Due to inconclusive
diagnosis, an intravenous contrast CT scan was ordered
and revealed a large amount of free peritoneal air and
free fluid. (Figure 1, 2) Moreover, a left upper quadrant
17 cm large mass originating from the stomach was
revealed along with secondary liver lesions. An urgent
laparotomy showed a prepyloric ulcer perforation and a
large inoperable mass arising from the pancreatic body
and largely invading the posterior wall of the stomach
occupying the upper abdomen with multiple hepatic sec-
ondary lesions. A liver biopsy was taken, the stomach
perforation was sutured closed and a washout was per-
formed. The histopathologic findings from the biopsy
material were consisted of small and medium size cystic
lesions surrounded and divided by hyalloid collagenous
matrix. The cysts were lined by cuboidal epithelial cells
with clear cytoplasm and round nuclei without atypical
or mitotic activity as demonstrated by pathology. The
glycogen content was documented by PAS positive reac-
tion. These findings were consistent with serous micro-
cystic adenoma of the pancreas and the malignant nature
of the tumor was confirmed by the presence of the exten-
sive invasive large inoperable pancreatic mass with hepa-
tic metastasis. The patient after a brief period in intensive
care unit for respiratory problems recovered from sur-
gery in 10 days but died a month later because of other,
unrelated, serious medical problems.
Conclusions
The prevalence of cancer among serous cystadenomas is
reported to be 3% since the first case reported in the lit-
erature in 1989. It is rather clear from the literature that
the differentiation between benign and malignant serous
cystadenoma both histologically and clinically may be
very difficult [9-11]. Additionally the presenting symp-
toms are not characteristic. To date serous cystadenoma
is considered malignant when tumor invasion of sur-
rounding tissues and organs or distant metastases are
present [4]. According to the literature most cases of
serous cystadenocarcinoma show synchronous or meta-
chronous liver metastases, lymph node infiltration, sple-
nic invasion, splenic vein infiltration and thrombosis,
neural, perineural, and stromal invasion, as well as sto-
mach, lung, adrenals, peritoneal, and colonic mesentery
metastases [12-14]. Nowadays, the current management
of serous cystadenomas of the pancreas is essentially
conservative. In fact, once diagnosed correctly through
CT scans, MRI, EUS, FNA, serology and blood test stu-
dies, observation and routinely reassessment of asympto-
matic lesions is indicated thereby avoiding a major
operation and resulting morbidity and mortality [1-3].
In our department we practice a six monthly follow-up.
Nevertheless, clinicians should be aware of the possibi-
lity for malignant transformation in serous cystic neo-
plasms and should maintain a high index of suspicion
when certain clues appear. These include the onset of
new symptoms, worsening of symptoms, or rapid enlar-
gement of the mass [15]. In these cases, resection may
be indicated, despite the lack of objective evidence for
malignancy obtained from preoperative imaging, endo-
scopy, and biopsies [3,13,15-17]. Our trust multidisci-
plinary specialist team board adopts and agrees with the
conservative approach in the majority of the benign
cases. Although, considering the chance of malignant
transformation, our policy is to strictly discuss the treat-
ment options with the patient and propose radical sur-
gery especially in young and fit patients where the
clinical and radiological situation of their lesions is
minimally doubtful, unclear or borderline.
In the present case the course of the disease was indo-
lent and only discovered after a co morbid condition
requiring admission to the hospital. This case demon-
strates that conservative management often does not have
the success hoped for. In fact, the best results are guaran-
teed in those cases where patients are closely followed up
and attended to their scheduled scans.
Cystic lesions of the pancreas are a heterogeneous
group of disorders, newly defined, with varied biological
behavior. The prevalence of such neoplasms is increasing.
The reason is probably due to the spread and efficacy of
diagnostic tools which frequently pick up, cystic pancrea-
tic lesions in asymptomatic patients as incidental finding
[17,18]. A thorough knowledge and experience on the
matter by the surgical team is more than important in
order to have a proper classification and treatment of
these conditions. The morphological study of these
tumors is based on the following investigations: ultra-
sound, CT scans MRI and EUS with FNA. Among this
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group of lesions, the serous cystadenoma is typically
asymptomatic; not requiring any treatment and simple
observation is the option of choice [19-21]. Serous cystic
neoplasms of the pancreas although they carry a realistic
risk of malignancy, the predominant view is that they
never become malignant. In our opinion the treatment
strategy of cystic serous neoplasms of the pancreas
should be aggressive, although evidence for that is weak
since it is largely based on case reports. Consequently,
more studies are needed to set treatment guidelines for
serous cystic neoplasms of the pancreas. Surgical treat-
ment is considered necessary only for symptomatic
patients or in cases of diagnostic doubt mainly because of
the perioperative risks of radical pancreatic surgery espe-
cially when a benign disease is addressed. Whilst the
management of intraductal papillary mucinous neo-
plasms and mucinous cystic neoplasms of the pancreas is
regulated by an extended literature and even by interna-
tional consensus guidelines, for the benign or borderline
serous neoplasms of the pancreas a shared management
vision is still needed. As mentioned, our clinical behavior
has recently turned towards a greater focus on surgery.
We consider that surgery of the body and especially the
tail of the pancreas is technically safe and feasible with
improved rates of morbidity and mortality and better
impact on patient thanks to new surgical tools, better
surgical materials, new technology and new advance-
ments in surgery such as the minimally invasive access.
Furthermore, pancreatic surgery is practiced in high
volume centers with great experience, thus minimizing
perioperative morbidity and mortality [22]. Thus, in
selected patients with benign pancreatic serous cystic
lesions of considerable size and a borderline clinical
behavior, after a short period of clinical and radiological
followup, we feel that a surgical treatment must be
offered.
Considering the current numbers and the future trend
of this matter, a consensus review of the management of
the whole spectrum of the cystic pancreatic neoplasms is
needed. Although, practice guidelines are missing, in
Figure 1 Large amount of free peritoneal air and free fluid alongside with evidence o metastatic liver disease.
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cases of cystic serous cystadenomas, an extensive discus-
sion with the patients on the management options must
be offered.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Author details
1LAIKON Hospital, First Department of Surgery, University of Athens Medical
School, Greece. 2HPB Surgery, Nicosia Surgical Department, Cyprus.
3Hepatobiliary and Pancreatic Surgical Department, Oxford Radcliffe Hospitals
NHS Foundation Trust. 4Churchill Hospital, Oxford, UK.
Authors’ contributions
BK, PA, PA, FE were the surgical team involved in the management of the
patient. ME performed the pathological assessment. BN and MA designed
and co-wrote the paper. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 March 2011 Accepted: 8 March 2012
Published: 8 March 2012
References
1. Siech M, Tripp K, Schmidt-Rohlfing B, Mattfeldt T, Widmaier U, Gansauge F,
Görich J, Beger HG: Cystic tumors of the pancreas: Diagnostic accuracy,
pathologic observations and surgical consequences. Langenbecks Arch
Surg 1998, 383:56-61.
2. Horvath K, Charbot JA: An aggressive resectional approach to cystic
neoplasms of the pancreas. Am J Surg 1999, 178:262-274.
3. Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW,
Fernandezdel Castillo C: Serous cystadenoma of the pancreas: Tumor
growth rates and recommendations for treatment. Ann Surg 2005,
242:413-421.
4. Bosman FT, Carneiro F, Hruban RH, Theise ND: WHO Classification of
Tumors of the Digestive System. IARC WHO Classification of Tumors;, 43,
No3.
5. Compagno J, Oertel JE: Microcystic adenomas of the pancreas(glycogen-
rich cystadenomas). Am J Clin Pathol 1978, 69:289-298.
6. Compagno J, Oertel JE: Mucinous cystic neoplasms of the pancreas with
overt and latent malignancy (cystadenocarcinoma and cystadenoma): A
clinicopathological study of 41 cases. Am J Clin Parhol 1978, 69:573-580.
7. Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH: Histological
typing of tumors of the exocrine pancreas. WHO international histological
classification of tumors. 2 edition. Berlin: Springer; 1996.
8. George DH, Murphy F, Michalski R, Ulmer BG: Serous cystadenocarcinoma
of the pancreas: A new entity? 1989, 13:61-66.
Figure 2 A left upper quadrant 17 cm originating from the stomach along with multiple secondary liver lesions.
Bramis et al. World Journal of Surgical Oncology 2012, 10:51
http://www.wjso.com/content/10/1/51
Page 4 of 5
9. Jonathan CKing, Tina TNg, Stephen CWhite, Cortina Galen, Howard AReber,
Joe Hines O: Pancreatic Serous Cystadenocarcinoma: A case report an
review of the literature. J Gastrointest Surg 2009, 13:1864-1868.
10. Galanis C, Zamani A, Cameron JL, Campell KA, Lillemoe KD, Caparelli D,
Chang D, Hruban RH, Yeo CJ: Resected serous cystic neoplasms of the
pancreas: A review of 158 patients with recommendations for
treatment. J Gastrointest Surg 2007, 11:820-826.
11. Schmidt-Rohlfing B, Siech M, Mattfeldt T, Schoenberg MH, Bager HG: Cystic
neoplasms of the pancreas: surgical treatment and outcome. Z
Gastroenterol 1998, 36:939-945.
12. Wu CM, Fisherman EK, Hruban RK: Serous cystic neoplasm involving the
pancreas and liver: A unusual clinical entity. Abdom Imaging 1999,
24:75-77.
13. Kimura W, Makuuchi M: Operative indications for cystic lesions of the
pancreas with malignant potential: Our experience.
Hepatogastroenterology 1999, 46:483-491.
14. Abe H, Kubota K, Mori M, Miki K, Minagawa M, Noise T, Kimura W,
Makuutchi M: Serous cystadenoma of the pancreas with invasive growth:
Benign or malignant? Am J Gastroenterol 1989, 93:1963-1966.
15. Strobel O, Z’graggen K, Schmitz-Winnenthal FH, Friess H, Kappeler A,
Zimmermann A, Uhl W, Buchler MW: Risk of malignancy in serous cystic
neoplasms of the pancreas. Digestion 2003, 68:24-33.
16. Friebe V, Keck T, Mattem D, Schmidt-Graeff A, Wemer M, Mikami Y,
Adam U, Hopt UT: Serous cystadenocarcinoma of the pancreas:
Management of a rare entity. Pancreas 2005, 31:182-187.
17. Verbesey JE, Munson JL: Pancreatic cystic neoplasms. Surg Clin N Am 90
2010, 411-425.
18. Federle M, Mc Grath K: Cystic neoplasms of the pancreas. Gastroenterol
Clin N Am 36 2007, 365-376.
19. Allen PJ, Jaques DP, D’Angelica M, Bowne WB, Conlon KC, Brennan MF:
Cystic lesions of the pancreas: selection criteria for operative and non
operative management in 209 patients. J Gastrointest Surg 7 2003,
970-977.
20. Garcea G, Ong SL, Rajesh A, Neal CP, Pollard CA, Berry DP, Dennison AR:
Cystic lesions of the pancreas. A diagnostic and management dilemma.
Pancreatology 2008, 8(3):236-51.
21. Ferrone CR, Correa-Gallego C, Warshaw AL, Brugge WR, Forcione DG,
Thayer SP, Fernandez-del Castillo C: Current trends in pancreatic cystic
neoplasms. Arch Surg 2009, 144(5):448-54.
22. McKay A, Sutherland FR, Bathe OF, Dixon E: Morbidity and mortality
following multivisceral resections in complex hepatic and pancreatic
surgery. J Gastrointest Surg 2008, 12(1):86-90.
doi:10.1186/1477-7819-10-51
Cite this article as: Bramis et al.: Serous cystadenocarcinoma of the
pancreas: report of a case and management reflections. World Journal of
Surgical Oncology 2012 10:51.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bramis et al. World Journal of Surgical Oncology 2012, 10:51
http://www.wjso.com/content/10/1/51
Page 5 of 5
